[Effectiveness of treatment of tuberculous meningoencephalitis]. 1981

O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest

UI MeSH Term Description Entries
D008297 Male Males
D008590 Meningoencephalitis An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions. Cerebromeningitis,Encephalomeningitis,Cerebromeningitides,Encephalomeningitides,Meningoencephalitides
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
October 1950, Ugeskrift for laeger,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
January 1953, Revista de sanidad y asistencia social,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
January 1951, Archivos. Hospital Universitario General Calixto Garcia,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
December 1953, Vie medicale (Paris, France : 1920),
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
January 2010, Medicinski arhiv,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
November 1983, Wiadomosci lekarskie (Warsaw, Poland : 1960),
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
July 2006, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
June 1997, Revista de neurologia,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
December 1980, Gaceta medica de Mexico,
O M Ivaniuta, and A V Panasiuk, and N N Kovalenko, and Iu A Zaika, and L Iu Shelest
August 1999, Medizinische Klinik (Munich, Germany : 1983),
Copied contents to your clipboard!